Abstract
In December 2019, a new severe acute respiratory coronavirus (SARS- COV-2) had caused outbreaks of pneumonia in Wuhan city, China. It was known as coronavirus infected disease-2019 (COVID-19). COVID-19 patients typically have a fever and respiratory syndrome, where the lung is the main target organ affected by this virus. The objective of this review is to monitor and evaluate injuries caused by the SARS-COV-2 virus on multiple organs other than the lung as the gastrointestinal tract, liver, kidney, heart, ovary, ocular, olfactory, gonad, skin, central nervous system, and sense organs. As SARS- COV-2 virus enters host cells via cell receptor angiotensin circulating enzyme-2 (ACE2), so it is important to identify the main target cells attacked by SARS- COV-2 virus by comparing the ACE2 expression and viral upload in different organs. In conclusion, the definite role of body organs is explored in the manifestation of COVID-19 infection and crosstalk between other organs are useful tools to find any correlation between disease severity and organs dysfunction, exact prognosis, disease prevention measures, clinical care, and treatment strategies.
Keywords: COVID-19, viral detection, organs crosstalk, organs dysfunction, prognosis, clinical care.
Graphical Abstract
Coronaviruses
Title:COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Volume: 2 Issue: 10
Author(s): Manal A. Hamed*
Affiliation:
- Department of Therapeutic Chemistry, National Research Centre, Dokki, Giza,Egypt
Keywords: COVID-19, viral detection, organs crosstalk, organs dysfunction, prognosis, clinical care.
Abstract: In December 2019, a new severe acute respiratory coronavirus (SARS- COV-2) had caused outbreaks of pneumonia in Wuhan city, China. It was known as coronavirus infected disease-2019 (COVID-19). COVID-19 patients typically have a fever and respiratory syndrome, where the lung is the main target organ affected by this virus. The objective of this review is to monitor and evaluate injuries caused by the SARS-COV-2 virus on multiple organs other than the lung as the gastrointestinal tract, liver, kidney, heart, ovary, ocular, olfactory, gonad, skin, central nervous system, and sense organs. As SARS- COV-2 virus enters host cells via cell receptor angiotensin circulating enzyme-2 (ACE2), so it is important to identify the main target cells attacked by SARS- COV-2 virus by comparing the ACE2 expression and viral upload in different organs. In conclusion, the definite role of body organs is explored in the manifestation of COVID-19 infection and crosstalk between other organs are useful tools to find any correlation between disease severity and organs dysfunction, exact prognosis, disease prevention measures, clinical care, and treatment strategies.
Export Options
About this article
Cite this article as:
Hamed A. Manal *, COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk, Coronaviruses 2021; 2 (10) : e170821191026 . https://dx.doi.org/10.2174/2666796702666210202124650
DOI https://dx.doi.org/10.2174/2666796702666210202124650 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Drugs of Abuse: An Update
Mini-Reviews in Organic Chemistry Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases
Current Vascular Pharmacology Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications
Current Pharmaceutical Design Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure
Current Pharmaceutical Design Oxidative Biotransformation of Fatty Acids by Cytochromes P450: Predicted Key Structural Elements Orchestrating Substrate Specificity, Regioselectivity and Catalytic Efficiency
Current Drug Metabolism Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Cardiac and Vascular Impairment in Patients with Mild Psoriasis: A Longitudinal Study
Current Vascular Pharmacology Advances in Chagas Disease Chemotherapy
Anti-Infective Agents in Medicinal Chemistry Anti-HER2 Cancer Therapy and Cardiotoxicity
Current Pharmaceutical Design Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects
Current Pharmaceutical Design Studying the Ethno-Pharmacological Basis of Antiepileptic Activity of Medhya Rasayanas- A Nootropic Package From Ayurveda
Current Traditional Medicine COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection
Coronaviruses